Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 85Lymphoma, Follicular 18Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms, Plasma Cell 8Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma, Mantle-Cell 4Hematologic Diseases 4Smoldering Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Disease Progression 3Paraproteinemias 2Myelodysplastic Syndromes 2Disease 2Anemia 2Sezary Syndrome 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Limb-girdle muscular dystrophy, type 2C 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Lenalidomide 3capivasertib 2Bortezomib 2tivozanib 1Zoledronic Acid 1Vitamin D 1Temozolomide 1Radiotherapy 1Nivolumab 1Gemcitabine 1Fulvestrant 1Etoposide 1Dexamethasone 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1Calcium 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Disease Progression × Lenalidomide × Clear all
NCT01191060 2026-04-06

IFM/DFCI2009

University Hospital, Toulouse

Phase 3 Completed
700 enrolled
Plasma cell

Disease Progression, Neoplasms, Plasma Cell

NCT01109004 2021-12-09

BMT CTN 0702

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
758 enrolled 21 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT02322320 2020-05-11

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
273 enrolled 16 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡